About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Kashiv BioSciences Announces Completion of Enrollment for Phase III Clinical Trial of ADL018, a Biosimilar Candidate to XOLAIR® (omalizumab)

Kashiv BioSciences, LLC today announced the completion of patient enrollment for its Phase III clinical trial of ADL018, a biosimilar candidate to XOLAIR®. This pivotal study aims to compare the efficacy, safety, tolerability, and immunogenicity of ADL018 with XOLAIR® in patients with chronic idiopathic/spontaneous urticaria (CSU) who remain symptomatic despite taking H1 antagonists. This clinical trial enrolled total 600 patients across multiple sites globally (NCT05774639). The Phase 1 PK/PD study in healthy volunteers was successfully concluded in June 2023 (NCT05413161).

“We are delighted to announce the completion of patient enrollment for our global Phase III trial of ADL018, our most advanced biosimilar candidate following the FDA approval of Releuko® and Fylnetra® in 2022. This milestone underscores our commitment to advancing our biosimilar pipeline and providing cost-effective therapeutic options,” said Dr. Sandeep Gupta, Chief Executive Officer of Kashiv.

“The completion of enrollment for our Phase III trial of ADL018 is a significant achievement for Kashiv, highlighting exceptional capabilities of our team. We are focused on the successful completion of this study and are excited about the potential impact of ADL018 on patients suffering with CSU and other chronic conditions for which omalizumab is approved,” said Dr. Chandramauli Rawal, Chief Operating Officer of Kashiv.

About ADL018

ADL018, a humanized monoclonal antibody designed to inhibit the binding of IgE to FcεR on the surface of mast cells and basophils, is being developed as a biosimilar to XOLAIR® (omalizumab), an injectable prescription medicine approved to treat CSU in individuals aged 12 and older who continue to have hives uncontrolled by H1 antagonists. Omalizumab is also approved for treating moderate to severe persistent asthma in individuals aged 6 and older whose asthma symptoms are not well controlled with inhaled corticosteroids, chronic rhinosinusitis with nasal polyps in individuals aged 18 and older, and IgE-mediated food allergy in adult and pediatric patients aged 1 year and older.

ADL018 matches the pharmaceutical presentations, dosage strength, route of administration, and dosing regimen of the U.S. and EU-approved omalizumab. According to IQVIA, worldwide sales of XOLAIR® in the twelve months preceding March 2024 were approximately $4.5 billion.

About Kashiv BioSciences, LLC

Kashiv BioSciences, LLC is a fully integrated biopharmaceutical company with comprehensive capabilities in global R&D, clinical development, regulatory affairs, and manufacturing of biosimilars and other complex products. The Company has a robust pipeline of more than eight biosimilars, alongside multiple 505(b)(2) and complex peptide generic products in development. Kashiv is headquartered in Piscataway, NJ with R&D and GMP manufacturing facilities in Piscataway, FDA-approved GMP manufacturing facilities in Chicago, IL, and state-of-the-art R&D infrastructure in Ahmedabad, India. Kashiv is establishing a robust network of strategic commercial partnerships, enhancing our global reach, and harnessing local expertise across key markets including US, Europe, Australia, Latin America and Canada.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.